Fulcrum Therapeutics, Inc. Banner Image

Fulcrum Therapeutics, Inc. has reached its limit for free report views

Work for Fulcrum Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Fulcrum Therapeutics, Inc.

  • Ticker FULC
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Fulcrum Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinicalMore development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and is advancing losmapimod to Phase 3 for the treatment of COVID-19. Fulcrum also anticipates filing an IND in the third quarter with initiation of a clinical trial in the fourth quarter of 2020 with FTX-6058 for the treatment of sickle cell disease.
Fulcrum Therapeutics, Inc.

Most Recent Annual Report

Fulcrum Therapeutics, Inc. MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Fulcrum Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports